The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With Immediate Haploidentical Plus Unrelated Cord Donor Search Versus Matched Unrelated Donor Search For AML And High-Risk MDS Patients
- Conditions
- Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2016-01-07
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 9
- Registration Number
- NCT02648932
- Locations
- 🇺🇸
University of Chicago Cancer Center, Chicago, Illinois, United States
A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)
- Conditions
- Leukemia, Myeloid, AcuteMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2015-12-29
- Last Posted Date
- 2018-10-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 28
- Registration Number
- NCT02641002
- Locations
- 🇺🇸
Mayo Clinic Phoenix, Phoenix, Arizona, United States
🇺🇸UCLA Division of Hematology Oncology, Los Angeles, California, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
A Phase 1 study to test the safety of an oral investigational drug (either AG-120 or AG-221) in combination with standard chemotherapeutic treatment for patients newly diagnosed with a blood malignancy (AML) with an IDH1 mutation and/or IDH2 mutation
- Conditions
- Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2 Mutation
- Interventions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2025-04-30
- Target Recruit Count
- 2
- Registration Number
- 2024-511380-29-00
- Locations
- 🇳🇱
Stichting Amsterdam UMC, Amsterdam, Netherlands
A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 49
- Registration Number
- NCT02632721
- Locations
- 🇺🇸
Mayo Clinic Cancer Center, Jacksonville, Florida, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Northwell Health, Lake Success, New York, United States
Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS
- Conditions
- Acute Myeloid Leukemia (AML)Hematopoietic Stem Cell Transplant (HSCT)Myelodysplastic Syndrome (MDS)
- Interventions
- Drug: Reduced-Intensity Conditioning RegimenDrug: Myeloablative Conditioning Regimen
- First Posted Date
- 2015-12-10
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Randy Windreich
- Target Recruit Count
- 21
- Registration Number
- NCT02626715
- Locations
- 🇺🇸
UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML
- Conditions
- Relapsed/Refractory Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2015-12-10
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT02626338
- Locations
- 🇺🇸
University of Arkansas, Little Rock, Arkansas, United States
🇺🇸City of Hope Medical Center, Duarte, California, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy
- Conditions
- FLT3 Mutation, Internal Tandem Duplication (ITD) or Tyrosine Kinase Domain (TKD)Acute Myeloid Leukemia (AML) With
- First Posted Date
- 2015-12-08
- Last Posted Date
- 2020-07-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT02624570
- Locations
- 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸The Jordan Research and Education Center ABSMC Comprehensive Cancer Ctr, Berkeley, California, United States
🇺🇸City of Hope National Medical Center Department of Hematology & HCT, Duarte, California, United States
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: AGS67E
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT02610062
- Locations
- 🇺🇸
Site US0006, Duarte, California, United States
🇺🇸Site US0004, New York, New York, United States
🇺🇸Site US0001, Houston, Texas, United States
Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL)
- Conditions
- Acute Myeloid LeukemiaAcute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2015-10-27
- Last Posted Date
- 2020-02-26
- Lead Sponsor
- ADC Therapeutics S.A.
- Target Recruit Count
- 35
- Registration Number
- NCT02588092
- Locations
- 🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸Northside Hospital, Atlanta, Georgia, United States
🇺🇸The University of Chicago Medical Center, Chicago, Illinois, United States
Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients
- Conditions
- AML
- Interventions
- Biological: Lintuzumab-Ac225
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2023-07-20
- Lead Sponsor
- Actinium Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT02575963
- Locations
- 🇺🇸
UCLA Medical Center, Division of Hematology/Oncology, Los Angeles, California, United States
🇺🇸University of Kentucky, Markey Cancer Center, Lexington, Kentucky, United States
🇺🇸University of Louisville, James Graham Brown Cancer Center, Louisville, Kentucky, United States